Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb 20:3:14-21.
doi: 10.2174/1874325000903010014.

Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice

Jose R Caeiro Rey  1 , Eduardo Vaquero Cervino, Maria Luz Rentero, Emilio Calvo Crespo, Angel Oteo Alvaro, Marta Casillas
Affiliations

Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice

Jose R Caeiro Rey et al. Open Orthop J. .

Abstract

Raloxifene, a member of the class of selective estrogen receptor modulators (SERM), reproduces the beneficial effects of estrogens on the skeletal systems, without the negative effects estrogens on breast and endometrium. This is a review article summarizing its mechanism, effects on bone and its applicability in traumatology clinical practice. In postmenopausal osteoporosis, this drug has been proven to decrease accelerated bone turnover, increase bone mineral density (BMD), and to structurally recover bone, decreasing the risk of vertebral fractures and the risk of non-vertebral fractures in patients with previous, severe vertebral fractures. Moreover, raloxifene appears to lower the risk of invasive breast cancer. Raloxifene would be efficacious in the prevention and treatment of postmenopausal osteoporosis.We can therefore conclude that raloxifene would be efficacious in the prevention and treatment of postmenopausal osteoporosis, while reducing the risk of breast cancer when used at the indicated dose of 60 mg/day and with a low incidence of side effects.

Keywords: Raloxifene; SERM; osteoporotic fracture.; postmenopausal osteoporosis.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Raloxifene’s chemical structure.
Fig. (2)
Fig. (2)
Raloxifene’s mechanism of action.
Fig. (3)
Fig. (3)
Variation of bone turnover markers from baseline to endpoint from the MORE Study (36 months).
See this image and copyright information in PMC

References

    1. Muñoz-Torres M, Alonso G, Mezquita RP. Prevención y tratamiento de la osteoporosis. Endocrinol Nutr. 2003;50:1–7.
    1. Brown JP, Josse RG. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J. 2002;167(Suppl 10):S1–S34. - PMC - PubMed
    1. Stevenson JC, Baum M. Hormone replacement therapy. Should be used selectively. BMJ. 1994;309(6948):191–2. - PMC - PubMed
    1. Hillard TC, Whitcroft SJ, Marsh MS, et al. Long-term effects of transdermal and oral hormone replacement therapy on postmeno-pausal bone loss. Osteoporos Int. 1994;4(6):341–8. - PubMed
    1. Kanis JA, Stevenson JC. Effect of estrogen therapy on bone density in elderly women. N Engl J Med. 1994;330(10):715–716. author reply. - PubMed

LinkOut - more resources